AEterna Zentaris (AEZS) Rips Following AEZS-130 Phase 3 Data
Tweet
Share
E-mailGet Alerts AEZS Hot Sheet
Join SI Premium – FREE
AEterna Zentaris Inc. (Nasdaq: AEZS), shares are ripping higher pre-market Tuesday, following AGHD test AEZS-130 reached its primary endpoint in Phase 3 testing.
Shares are currently up 15.3 percent.
Shares are currently up 15.3 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Ionis Pharma's therapy to treat rare genetic disorder
- Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
